Descargar la presentación
La descarga está en progreso. Por favor, espere
1
Effectiveness of mycophenolate mofetil in C3 glomerulonephritis
Cristina Rabasco, Teresa Cavero, Elena Román, Jorge Rojas-Rivera, Teresa Olea, Mario Espinosa, Virginia Cabello, Gema Fernández- Juarez, Fayna González, Ana Ávila, José María Baltar, Montserrat Díaz, Raquel Alegre, Sandra Elías, Monserrat Antón, Miguel Angel Frutos, Alfonso Pobes, Miguel Blasco, Francisco Martín, Carmen Bernis, Manuel Macías, Sergio Barroso, Alberto de Lorenzo, Gema Ariceta, Manuel López-Mendoza, Begoña Rivas, Katia López-Revuelta, José María Campistol, Santiago Mendizábal, Santiago Rodríguez de Córdoba, Manuel Praga Kidney International Volume 88, Issue 5, Pages (November 2015) DOI: /ki Copyright © 2015 International Society of Nephrology Terms and Conditions
2
Figure 1 Renal survival (defined by a status free of end-stage renal disease) in patients treated with MMF (MMF-IST), other IST (other-IST), and no IST (non-IST). ESRD, end-stage renal disease; IST, immunosuppressive treatments; MMF, mycophenolate mofetil. Kidney International , DOI: ( /ki ) Copyright © 2015 International Society of Nephrology Terms and Conditions
3
Figure 2 Individual clinical course of 22 C3 glomerulonephritis (C3GN) patients treated with mycophenolate mofetil (MMF). ‘0’ represents the onset of MMF treatment. Numbers represent serum creatinine values (mg/dl) at the onset of MMF and at the last follow-up visit in every patient. MMF was discontinued only in patients 4 and 6;the remaining 20 patients were receiving MMF at the last visit. Kidney International , DOI: ( /ki ) Copyright © 2015 International Society of Nephrology Terms and Conditions
Presentaciones similares
